Technology

Addressing sources of tension on differentiating types of data.

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.

With more promising products emerging, investment risks remain.

Hill shares her insights on what is needed for a turnaround in talent development.

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

What’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.

Continued push for latest technology in biopharma will advance collection of patient data.

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.

A new report examining pharma sector exposure makes for sobering reading, especially in US.

Obstacles in data exchange remain for industry.

Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.

Designing an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.

Providing ultimate value to stakeholders remains key in new style of development.

Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.

As the pressure on teams reviewing promotional content has increases, both in terms of volumes of content and complexity, Sameer Lal discusses the need for a near-term strategies using artificial intelligence (AI) and machine learning (ML) to decongest bottlenecks of the manual review process.

2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.

Meeting demands of the new marketplace.

In order to address data literacy gaps amongst reps and managers, sales trainers are increasingly turning to computer-based business simulation games, writes Jeremy Lovelace.

Critics proclaim that recent RWD guidance issued by FDA still has a good number of gaps to fill and may take some time to accomplish.

Practices to ensure accuracy in selected datasets.

The MIT Institute for Work and Employment Research’s Dr. Thomas Kochan offers three key insights on engaging with AI and other digital solutions as they continue to transform the working environment.

Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.

According to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.

Healthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.

How can pharma create solutions that are effective, can provide long-term value, and will actually be adopted by HCPs and patients?